X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives $34.50 Average PT from Brokerages

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been assigned an average recommendation of “Hold” from the five brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $34.50.

A number of equities research analysts have recently commented on XFOR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research report on Monday, December 29th. Zacks Research lowered X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 26th. Stifel Nicolaus set a $10.00 target price on X4 Pharmaceuticals and gave the company a “buy” rating in a report on Friday, December 5th. Finally, Wall Street Zen cut X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 30th.

X4 Pharmaceuticals Stock Performance

NASDAQ:XFOR opened at $3.98 on Friday. The company has a 50-day moving average of $3.82 and a 200-day moving average of $3.36. The firm has a market cap of $348.01 million, a price-to-earnings ratio of -0.39 and a beta of 0.46. The company has a current ratio of 5.65, a quick ratio of 5.48 and a debt-to-equity ratio of 1.23. X4 Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $20.10.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Wednesday, November 5th. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.10. The business had revenue of $1.77 million during the quarter, compared to analyst estimates of $2.05 million. X4 Pharmaceuticals had a negative net margin of 279.86% and a negative return on equity of 343.67%. Analysts forecast that X4 Pharmaceuticals will post -0.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On X4 Pharmaceuticals

Large investors have recently made changes to their positions in the company. Rhumbline Advisers lifted its position in shares of X4 Pharmaceuticals by 5.4% in the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after acquiring an additional 9,690 shares in the last quarter. Two Sigma Investments LP acquired a new stake in X4 Pharmaceuticals during the 3rd quarter valued at $47,000. Bank of America Corp DE lifted its holdings in shares of X4 Pharmaceuticals by 20.3% in the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after purchasing an additional 22,485 shares in the last quarter. Jane Street Group LLC boosted its position in shares of X4 Pharmaceuticals by 112.5% in the second quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock worth $185,000 after buying an additional 51,544 shares during the period. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of X4 Pharmaceuticals in the third quarter worth $326,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.